Core Viewpoint - The announcement by China National Pharmaceutical Group Modern (国药现代) regarding the transfer of drug marketing authorization for lactulose oral solution from Anhui Meilai to its subsidiary, Guoyao Zhijun Ping Shan, aligns with the company's long-term strategic development plan and aims to enhance its product pipeline in chronic disease treatment [1] Group 1 - The total transfer fee for the drug marketing authorization is RMB 5.86 million [1] - Lactulose is an osmotic laxative primarily used for treating chronic functional constipation and also serves as a prebiotic to regulate gut microbiota [1] - The acquisition of the lactulose oral solution marketing authorization is expected to strengthen Guoyao Zhijun Ping Shan's market competitiveness without significantly impacting the company's current operating performance [1]